| Clopidogrel n = 21 | Ticagrelor n = 21 | p-value |
---|---|---|---|
Males | 17 (80.9%) | 20 (95.2%) | ns |
Females | 4 (19%) | 1 (4.7%) | ns |
Age (years) | 57.9 ± 7.04 | 53.71 ± 9.33 | ns |
Risk factors | |||
 Hypertension | 11 (52.3%) | 9 (42.8%) | ns |
 Dyslipidemia | 7 (33.3%) | 8 (38%) | ns |
 Diabetes | 7 (33.3%) | 4 (19%) | ns |
 Smokers | 17 (80.9%) | 18 (85.7%) | ns |
Laboratory parameters | |||
 Hematocrit (%) | 44.6 ± 4.28 | 43.54 ± 2.92 | ns |
 Platelet count (K/μl) | 276.4 ± 79.42 | 253 ± 81.07 | ns |
 Estimated glomerular filtration rate (ml/min) | 110.8 (62–130.8) | 95 (69.95–101) | ns |
Time intervals | |||
 Symptom-to-Needle time (hours) | 2.33 (2–5.2) | 1.92 (1.5–4.1) | ns |
 Needle-to-Balloon time (hours) | 33.25 ± 19.67 | 31.78 ± 20.27 | ns |
Successful thrombolysis | 19/21 (90.4%) | 20/21 (95.2%) | ns |
Fibrinolytic agent used | |||
 Tenecteplase | 21 (100%) | 21 (100%) | ns |
Concomitant medications at inclusion | |||
 Unfractionated heparin | 1 (4.76%) | 0 (0%) | ns |
 Low-molecular-weight heparin | 20 (95.2%) | 21 (100%) | ns |
 Aspirin | 21 (100%) | 21 (100%) | ns |
 Statin | 6 (28.57%) | 5 (23.8%) | ns |
 Beta-blocker | 4 (19%) | 3 (14.3%) | ns |
 Nitroglycerine | 7 (33.3%) | 6 (28.5%) | ns |
 Angiotensin converting enzyme/angiotensin receptor inhibitors | 5 (23.8%) | 7 (33.3%) | ns |
Medication at discharge from hospital | |||
 Aspirin | 21 (100%) | 21 (100%) | ns |
 High dose Statin | 21 (100%) | 21 (100%) | ns |
 Atorvastatin 40 or 80 mg | 16 (76.2%) | 14 (66.6%) | ns |
 Rosuvastatin 20 or 40 mg | 5 (23.8%) | 7 (33.3%) | ns |
 Beta-blockers | 16 (76%) | 17 (80%) | ns |
 Angiotensin converting enzyme/angiotensin receptor inhibitors | 18 (85.7%) | 16 (76%) | ns |
 Mineralocorticoid receptor antagonists | 2 (9.5%) | 3 (14.2%) | ns |